UNASSIGNED: 8551 Background: @entity1 with regionally disseminated @entity320 , @entity5 , have a variable prognosis with reported 5-year survival of 24-67%, depending on subcategory. There is a subgroup of @entity1 with a better long-term survival, even when known adverse pathological risk factors, such as macro- @entity3 , number of lymph node @entity3 and ulceration are taken into consideration. Identification of a molecular profile may predict subgroups of @entity1 with prognostic benefits of adjuvant treatments in @entity5 . METHODS: A RNA oligonucleotide microarray study was performed on lymph node @entity3 from 42 @entity1 with @entity9910 : 19 @entity1 with short survival (<=  14 months) and 23 with long survival (>=  60 months). Candidate genes were validated by qRT-PCR and IHC. RESULTS: Categorization according to the biological functions revealed @entity74 ( @entity74 ) clusters that are highly significantly differentially expressed between the prognosis groups. Two of the top categories were glycolysis ( @entity74 : 0006096) (p<0.001) and pigment biosynthetic process ( @entity74 : 0046148) (p<0.001). No single gene was significantly differentially expressed between the groups. Four genes from the two top @entity74 categories, @entity69036 , @entity7501 , @entity17341 and @entity18259 , were selected for validation. Best result is found for @entity69036 in both qRT-PCR (p=0.11) and IHC (p=0.012). The median relative quantity values for all mRNAs are lower for those with good outcome compared to those with poor outcome. When combining the results from IHC a significant finding was observed. High expression of at least two of these four gene products was found to be an independent adverse prognostic factor for overall survival in a multivariate analysis (p=0.037). CONCLUSIONS: We have identified a prognostic panel of four gene products associated with clinical outcome in @entity9910 .

A gene expression profile associated with clinical outcome in XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity69036 :: ('26330', 'Gene') :: ['GAPDHS'] @entity5 :: ('MESH:D009369', 'Disease') :: ['stage III', 'stage III disease'] @entity7501 :: ('2597', 'Gene') :: ['GAPDH'] @entity17341 :: ('5315', 'Gene') :: ['PKM2'] @entity74 :: ('MESH:D030342', 'Disease') :: ['gene ontology', 'GO'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis', 'metastases'] @entity9910 :: ('MESH:C563985', 'Disease') :: ['stage III melanoma'] @entity18259 :: ('7306', 'Gene') :: ['TYRP1'] @entity320 :: ('MESH:D008545', 'Disease') :: ['malignant cutaneous melanoma']
@entity9910 :: (MESH:C563985,Disease) :: ['stage III melanoma']
